SYN Synthetic Biologics Dashboard

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Company profile

Ticker

SYN

Exchange

AMEX

Website

www.syntheticbiologics.com

CEO

Steven A. Shallcross

Incorporated

Nevada

Location

Maryland

Fiscal year end

Dec 31

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

ADEONA PHARMACEUTICALS, INC., PIPEX PHARMACEUTICALS, INC., SHEFFIELD MEDICAL TECHNOLOGIES INC, SHEFFIELD PHARMACEUTICALS INC

SEC CIK

0000894158

Corporate docs

Articles of Incorporation & Bylaws

IRS number

133808303

SYN stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Synthetic Biologics Announces First Patient Dosed In Phase 1b/2a Clinical Trial Of SYN-004 In Allogeneic Hematopoietic Cell Transplant Recipients

14 Apr 21

Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet

Synthetic Biologics Announces First Six Participants Dosed In Phase 1a Clinical Trial Of SYN-020 Intestinal Alkaline Phosphatase

1 Apr 21

Maxim Group Upgrades Synthetic Biologics to Buy

12 Mar 21

Maxim Group analyst Jason McCarthy upgrades Synthetic Biologics (AMEX:SYN) from Hold to Buy.

Earnings Scheduled For March 4, 2021

4 Mar 21

Synthetic Genomics Receives Notice Of Allowance For U.S. Patent Titled 'Recombinant Algal Microorganisms Having Increased Lipid Production, and Methods of Making and Using the Same'

1 Mar 21

Press releases

Pro users get this 30m faster

Synthetic Biologics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

14 Apr 21

ROCKVILLE, Md., April 14, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

Synthetic Biologics Announces First Six Participants Dosed in Phase 1a Clinical Trial of SYN-020 Intestinal Alkaline Phosphatase

1 Apr 21

ROCKVILLE, Md., April 1, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

Synthetic Biologics Reports 2020 Year End Operational Highlights and Financial Results

4 Mar 21

ROCKVILLE, Md., March 4, 2021 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE:SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal

Synthetic Biologics, Inc. to Host Earnings Call

4 Mar 21

Synthetic Biologics to Report 2020 Year End Operational Highlights and Financial Results on March 4, 2021

25 Feb 21

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

4 Mar 21

17 Apr 21

31 Dec 21

Financial summary

Financial statements Chart SYN financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	6.23M	6.23M	6.23M	6.23M	6.23M	6.23M
Cash burn (monthly)	(positive/no burn)	734.83K	710.67K	846.67K	1.04M	1.01M
Cash used (since last report)	n/a	2.62M	2.53M	3.02M	3.72M	3.61M
Cash remaining	n/a	3.61M	3.69M	3.21M	2.51M	2.61M
Runway (months of cash)	n/a	4.9	5.2	3.8	2.4	2.6

Beta Read what these cash burn values mean

Recent insider trades

SYN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Dec 20	Steven A Shallcross	Stock Options Common Stock	Grant	Aquire A	No	No	0.417	450,000	187.65K	450,000
30 Dec 20	John J Monahan	Stock Options Common Stock	Grant	Aquire A	No	No	0.417	150,000	62.55K	150,000
30 Dec 20	Wolf Jeffrey Alan	Stock Options Common Stock	Grant	Aquire A	No	No	0.417	150,000	62.55K	150,000
30 Dec 20	Kraws Jeffrey J	Stock Options Common Stock	Grant	Aquire A	No	No	0.417	150,000	62.55K	150,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

SYN institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

5.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	24	23	+4.3%
Opened positions	5	0	NEW
Closed positions	4	6	-33.3%
Increased positions	5	5	–
Reduced positions	3	4	-25.0%

13F shares	Current	Prev Q	Change
Total value	2.72M	651K	+317.2%
Total shares	7.16M	1.37M	+423.4%
Total puts	0	0
Total calls	0	225K	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Hudson Bay Capital Management	2.22M	$850K	NEW
Custodian Ventures	1.96M	$728K	NEW
Renaissance Technologies	1.24M	$474K	+44.0%
Iroquois Capital Management	1.13M	$433K	NEW
Fisher Asset Management	125.7K	$48K	+108.4%
Bridgeway Capital Management	109.3K	$42K	0.0%
VIRT Virtu Financial	104.39K	$40K	NEW
Acadian Asset Management	72.79K	$28K	0.0%
Blair William & Co	54.54K	$21K	+3.2%
BLK Blackrock	38.21K	$14K	0.0%

Largest transactions	Shares	Bought/sold	Change
Hudson Bay Capital Management	2.22M	+2.22M	NEW
Custodian Ventures	1.96M	+1.96M	NEW
Iroquois Capital Management	1.13M	+1.13M	NEW
Renaissance Technologies	1.24M	+378K	+44.0%
VIRT Virtu Financial	104.39K	+104.39K	NEW
Vanguard	36.39K	-87K	-70.5%
Fisher Asset Management	125.7K	+65.37K	+108.4%
Susquehanna International	15.71K	+15.71K	NEW
NTRS Northern Trust	13.65K	-14.86K	-52.1%
Tower Research Capital	14.8K	+14.7K	+14695.0%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Qualigen Therapeutics • Immune Therapeutics

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abated, absenteeism, adequacy, AGP, Alameda, altogether, ANIX, Anixa, Artugen, ascending, AVGN, Baylor, biochemistry, Bordetella, CA, called, cap, carryback, celiac, Cellix, chart, clause, cleaning, climate, closure, contradictory, convene, curb, Deinove, discernable, disconnected, downturn, Dublin, dysfunction, economy, evolution, fatty, feasible, fire, flexibility, flexible, footnote, frailty, furlough, globe, heightening, Hodin, Houston, ill, inconsistent, incorrect, inflammatory, inflated, instability, Instructor, Ireland, John, leader, lifespan, MAD, McMaster, meantime, merged, Meridian, MGH, mice, Mitsubishi, Monahan, NAFLD, nationwide, NJ, noncompliance, Nutley, outbreak, overstating, political, predominantly, prespecified, proper, PTC, rapid, reliance, runway, SAD, sector, shipping, sick, skill, slowdown, social, Somatix, squeeze, steadily, stemming, strain, streamlined, subtopic, Surgery, sweeping, Tanabe, telemedicine, temporarily, terrorism, transmission, transport, Triton, TX, unblinded, underway, unique, visit, war, weather, Wuhan

Removed: AB, Abbreviated, ABR, acquirer, adaptive, added, Addendum, adolescence, adulthood, Allergan, alternating, amend, analyte, ANDA, annualized, anolo, antimethanogenic, anytime, applicant, Ardelyx, Assembly, AUC, Avenue, avoiding, behavior, belonging, bioequivalent, Black, branded, byM, calendar, California, career, certify, challenged, CIC, classification, clear, clinically, COBRA, commute, competitor, composite, composition, compounded, confident, considerably, constitute, consummated, consummation, contendere, converting, conviction, copy, correlation, crime, CSBM, curable, cured, depleting, depletion, dereliction, detectable, developer, discouraging, discovered, dishonesty, disorder, distance, divergent, Eagle, education, educational, EGRX, embezzlement, entrusted, Equivalence, execute, extraordinary, fault, FDCA, feedback, felony, fiduciary, filer, forC, Forest, forward, functional, gas, GlobalData, harassment, identifiedC, idiopathic, importance, incorporating, infringed, inhibiting, inhibition, innovation, innovative, innovator, insubordination, insulin, intending, invalid, inverse, invest, Ironwood, lactulose, lifted, lipid, lowered, lumen, marketer, mclean, meaningful, measurable, Meda, men, metabolite, Mevacor, misappropriation, MitsubishiTanabe, mixed, moiety, moral, movement, notify, observed, ofC, ofClostridium, Orange, overproduction, owner, paragraph, parenteral, participated, payroll, Pennsylvania, perception, pertussisinfection, PK, played, plea, ppm, precise, predominant, preferential, prepared, prescribe, prescribed, producing, promoted, proscribed, pursuit, ranking, ratably, ratio, referenced, Reincorporation, relocation, relying, remeasured, represented, responder, Rider, risky, rollover, SBM, score, Scott, screened, separation, shareholder, shortage, situated, Squibb, statistically, Stephen, stomach, struggled, sue, Supplementary, surviving, sustainability, Symptom, symptomatic, takeover, targeting, Tariff, technological, thatB, theB, theC, thereon, toC, top, transition, trough, turpitude, undetectable, unenforceable, unsubtyped, unused, USPTO, validation, vitro, withBordetella, withC, women, workplace, worst, ZIOPHARM

From filing 10-K 2020 FY